21 CFR
Part 212 Current Good Manufacturing Practice for Positron Emission Tomography Drugs
Subpart A - General Provisions
- § 212.1 What are the meanings of the technical terms used in these regulations?
- § 212.2 What is current good manufacturing practice for PET drugs?
- § 212.5 To what drugs do the regulations in this part apply?
Subpart B - Personnel and Resources
Subpart C - Quality Assurance
Subpart D - Facilities and Equipment
Subpart E - Control of Components, Containers, and Closures
Subpart F - Production and Process Controls
Subpart G - Laboratory Controls
- § 212.60 What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products? 55 × 483
- § 212.61 What must I do to ensure the stability of my PET drug products through expiry? 3 × 483
Subpart H - Finished Drug Product Controls and Acceptance
- § 212.70 What controls and acceptance criteria must I have for my finished PET drug products? 13 × 483
- § 212.71 What actions must I take if a batch of PET drug product does not conform to specifications? 19 × 483
Subpart I - Packaging and Labeling
- § 212.80 What are the requirements associated with labeling and packaging PET drug products? 1 × 483
Subpart J - Distribution
Subpart K - Complaint Handling
- § 212.100 What do I do if I receive a complaint about a PET drug product produced at my facility? 5 × 483